Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Anti-Cancer Drugs|April 25, 2003
Debate on the conservative and aggressive treatment options for the optimal management of indolent non-Hodgkin's lymphomaKevin R Imrie, David C Linch, Myron S Czuczman
Psycho-Oncology|October 24, 2008
The impact of follicular (FL) and other indolent non-Hodgkin's lymphomas (NHL) on work productivity-a preliminary analysisMatthew C Cheung, Kevin R Imrie, Jessica Friedlich, et al.
Cancer Treatment Reviews|January 24, 2007
Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care OntarioMatthew C Cheung, Adam E Haynes, Ralph M Meyer, et al.
Leukemia & Lymphoma|June 14, 2011
High-dose methotrexate based chemotherapy with deferred radiation for treatment of newly diagnosed primary central nervous system lymphomaLauren M Gerard, Kevin R Imrie, Joy Mangel, et al.
British Journal of Haematology|August 2, 2012
Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literatureHany R Guirguis, Matthew C Cheung, Mervat Mahrous, et al.
Annals of Hematology|March 21, 2007
Physician perceptions and preferences in the treatment of acquired immunodeficiency syndrome (AIDS)-related lymphomaMatthew C Cheung, Kevin R Imrie, Heather A Leitch, et al.
Hematological Oncology|May 1, 2018
Management of newly diagnosed high-risk and intermediate-risk follicular lymphoma with <sup>90</sup> Y ibritumomab tiuxetan in a phase II studyNeil L Berinstein, Nancy M Pennell, Rashmi Weerasinghe, et al.
Journal of the National Cancer Institute|April 15, 2015
Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12Matthew C Cheung, Annette E Hay, Michael Crump, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12Michael Crump, John Kuruvilla, Stephen Couban, et al.
Pageof 1